Mifepristone Makers Rush to Supreme Court to Block New Abortion Pill Restrictions
Danco Laboratories, the maker of the abortion pill mifepristone, has filed an emergency appeal at the Supreme Court demanding an immediate pause to a recent ruling by the 5th US Circuit Court of Appeals that reinstates strict in-person dispensing requirements nationwide.
The appeal, filed on Saturday, warns that the 5th Circuit’s decision injects “immediate confusion and upheaval” into time-sensitive abortion care across the country. The ruling would force patients to visit clinics or doctors in person to obtain the medication, reversing access gains made since the Covid-19 pandemic enabled telehealth delivery.
The move ignites a fresh legal battle just two years after the Supreme Court rejected a similar challenge, which allowed the medication to remain widely available by mail or at pharmacies. Danco’s attorneys questioned how patients will get pills if they cannot immediately secure in-person appointments, sparking concerns about care delays in states with increasingly restrictive abortion laws.
Backlash After Roe v. Wade Overturn
The 5th Circuit’s ruling follows the Supreme Court’s overturning of Roe v. Wade, which eliminated the federal constitutional right to abortion. Since then, many conservative states have sharply limited access to in-clinic abortions, making medication abortion the primary option.
According to recent research by the Guttmacher Institute, medication abortions accounted for more than 60% of all abortions in the US in 2026. The Biden administration responded by finalizing rules in 2026 that removed the longstanding requirement for in-person dispensing of mifepristone, expanding telehealth access nationwide.
However, the conservative 5th Circuit—covering Texas, Louisiana, and Mississippi—claimed these rules violate state abortion bans like Louisiana’s, which sued last year to block the updated federal regulation. A federal district court had previously declined action until the FDA could complete a safety review of mifepristone.
Mifepristone’s Safety Profile and Legal Stakes
Data analyzed by CNN confirm mifepristone is overwhelmingly safe, with fewer side effects reported compared to common medications such as penicillin or Viagra. Despite this, legal challenges continue to threaten patient access, especially in conservative regions.
The Supreme Court appeal, which was fast-tracked to conservative Justice Samuel Alito, recalls the urgency of broader abortion battles engulfing the US. The court now faces mounting pressure to clarify the availability of medication abortion at a time when millions rely on it for reproductive care.
What’s Next?
Danco called on the Supreme Court to issue an immediate administrative stay to halt the 5th Circuit’s decision while the case proceeds on the merits. If the Court declines, patients seeking mifepristone could face sudden obstacles to access at pharmacies and clinics nationwide starting this weekend.
For Delawareans and Americans nationwide, the outcome could reshape how abortion pills are obtained, impacting millions of women’s healthcare decisions in highly time-sensitive situations. This case also signals the continuing friction between federal authority and state abortion restrictions that will likely dominate the legal landscape this year.
The Delaware Herald will follow all developments on this fast-moving story as it unfolds.
